Cardiomyocyte apoptosis is related to left ventricular dysfunction and remodelling in dilated cardiomyopathy, but is not affected by growth hormone treatment

European Journal of Heart Failure

Volumn 9, Issue 2, 2007, Pages 160-167

  Ibe, Waltraut ^a   Saraste, Antti ^c   Lindemann, Stephan ^d   Bruder, Stephanie ^b   Buerke, Michael ^e   Darius, Harald ^f   Pulkki, Kari ^g   Voipio Pulkki, Liisa Maria ^g  

^a Suedharz Hospital Nordhausen   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c UNIVERSITY OF TURKU   (Finland)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^f VIVANTES KLINIKUM NEUKÖLLN   (Germany)

^g HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Cardiomyocyte apoptosis; Dilated cardiomyopathy; Growth hormone; Heart failure; Insulin like growth factor 1

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FAS ANTIGEN; HUMAN GROWTH HORMONE; PLACEBO; SOMATOMEDIN C;

ADULT; AGED; APOPTOSIS; ARTICLE; BLOOD SAMPLING; CELL FUNCTION; CELL STRUCTURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; ECHOCARDIOGRAPHY; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE BIOPSY; HEART MUSCLE CELL; HEART VENTRICLE REMODELING; HEART VENTRICLE VOLUME; HORMONAL THERAPY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MULTICENTER STUDY; NICK END LABELING; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

APOPTOSIS; CARDIOMYOPATHY, DILATED; FEMALE; HEART VENTRICLES; HUMAN GROWTH HORMONE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MYOCYTES, CARDIAC; SOMATOMEDINS; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33847786190     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2006.06.002     Document Type: Article

References (42)

1. Narula J., Haider N., Virmani R., et al. Apoptosis in myocytes in end-stage heart failure. N Engl J Med 335 (1996) 1182-1189
2. Olivetti G., Abbi R., Quaini F., Kajstura J., et al. Apoptosis in the failing human heart. N Engl J Med 336 16 (1997) 1131-1141
3. Kostin S., Pool L., Elsässer A., et al. Myocytes die by multiple mechanisms in failing human hearts. Circulation 92 (2003) 715-724
4. Saraste A., Pulkki K., Kallajoki M., et al. Cardiomyocyte apoptosis and progression of heart failure to transplantation. Eur J Clin Invest 29 (1999) 380-386
5. Hayakawa Y., Chandra M., Miao W., et al. Inhibition of cardiac myocyte apoptosis improves cardiac function and abolishes mortality in the peripartum cardiomyopathy of Galphaq transgenic mice. Circulation 108 (2003) 3036-3041
6. Frustaci A., Chimenti C., Setoguchi M., et al. Cell death in acromegalic cardiomyopathy. Circulation 99 (1999) 1426-1434
7. Gonzalez A., Lopez B., Ravassa S., et al. Stimulation of cardiac apoptosis in essential hypertension: potential role of angiotensin II. Hypertension (2002) 75-80
8. Petrovic D., Zorc-Pleskovic R., and Zorc M. Apoptosis and proliferation of cardiomyocytes in heart failure of different etiologies. Cardiovasc Pathol 9 (2000) 149-152
9. Lee W.L., Chen J.W., Ting C.T., et al. Insulin-like growth factor 1 improves cardiovascular function and suppresses apoptosis of cardiomyocytes in dilated cardiomyopathy. Endocrinology 140 (1999) 4831-4840
10. Buerke M., Murohara T., Skurk C., Nuss C., Tomaselli K., and Lefer A.M. Cardioprotective effect of insulin-like growth factor 1 in myocardial ischemia followed by reperfusion. Proc Natl Acad Sci U S A 92 (1995) 8031-8805
11. Wang L., Ma W., Markovich R., Chen J.W., and Wang P.H. Regulation of cardiomyocyte apoptotic signaling by insulin-like growth factor 1. Circ Res 83 (1998) 516-522
12. Fazio S., Sabatini D., Capaldo B., et al. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med 334 (1996) 809-814
13. Isgaard J., Bergh C.H., Caidahl K., Lomsky M., Hjalmarson A., and Bengtsson B.A. A placebo-controlled study of growth hormone in patients with congestive heart failure. Eur Heart J 19 (1998) 1704-1711
14. Osterziel K.J., Strohm O., Schuler J., et al. Randomized, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy. Lancet 351 (1998) 1233-1237
15. ACC/AHA guidelines for the clinical application of echocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee to Develop Guidelines for the Clinical Application of Echocardiography). Circulation 82 (1990) 2323-2345
16. Erbel R., Schweizer P., Meyer J., Krebs W., and Effert S. Quantification of the function of the left ventricle using 2-dimensional echocardiography. Ultraschall Med 4 4 (1983) 228-236
17. Buchwalsky R. Inflow catheter: technique and evaluation and practical consequences (1992), Perimed-Spitta 176-181 (German)
18. Bilfinger T.V. Error analysis of the thermoindicator method for the determination of heart failure. Anasth Intensivther Notfallmed 17 4 (1982) 215-219
19. Saraste A., Pulkki K., Kallajoki M., Henriksen K., Parvinen M., and Voipio-Pulkki L.M. Apoptosis in human acute myocardial infarction. Circulation 95 (1997) 320-323
20. Fortuno M.A., Ravassa S., Fortuno A., Zalba G., and Diez J. Cardiomyocyte apoptotic cell death in arterial hypertension: mechanisms and potential management. Hypertension 38 (2001) 1406-1412
21. Metzger M., Higuchi M.L., Moreira L.F., et al. Relevance of apoptosis and cell proliferation for survival of patients with dilated cardiomyopathy undergoing partial left ventriculectomy. Eur J Clin Invest 32 (2002) 394-399
22. Abbate A., Biondi-Zoccai G.G.L., Bussani R., et al. Increased myocardial apoptosis in patients with unfavourable left ventricular remodelling and early symptomatic post-infarction heart failure. J Am Coll Cardiol 41 (2003) 753-760
23. Duerr R.L., McKirnan M.D., Gim R.D., Clark R.G., Chien K.R., and Ross J. Cardiovascular effects of insulin-like growth factor-1 and growth hormone in chronic left ventricular failure in the rat. Circulation 93 (1996) 2188-2196
24. Isgaard J., Kujacic V., Jennische E., et al. Growth hormone improves cardiac function in rats with experimental myocardial infarction. Eur J Clin Invest 27 (1997) 517-525
25. Acevedo M., Corbalan R., Chamorro G., et al. Administration of growth hormone to patients with advanced cardiac heart failure: effects upon left ventricular function, exercise capacity, and neurohormonal status. Int J Cardiol 87 (2003) 185-191
26. Osterziel K.J., Ranke M.B., Strohm O., and Dietz R. The somatotrophic system in patients with dilated cardiomyopathy: relation of insulin-like growth factor-1 and its alterations during growth hormone therapy to cardiac function. Clin Endocrinol 53 (2000) 61-68
27. Volterrani M., Giustina A., Manelli F., Cicoira M.A., Lorusso R., and Giordano A. Role of growth hormone in chronic heart failure: therapeutic implications. Ital Heart J 1 (2000) 732-738
28. Anker S.D., Volterrani M., Pflaum C.D., et al. Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone. J Am Coll Cardiol 38 (2001) 443-452
29. Torre-Amione G., Kapadia S., Lee J., et al. Tumor necrosis factor alpha and tumor necrosis factor receptors in the failing human heart. Cirulation 93 (1996) 704-711
30. Yamamura T., Nakamura H., Yamamoto T., et al. Fas expression and apoptosis correlate with cardiac dysfunction in patients with dilated cardiomyopathy. Jpn Circ J 63 (1999) 149-154
31. Takemura G., Kato S., Aoyama T., Hayakawa Y., et al. Characterization of ultrastructure and its relation with DNA fragmentation in Fas-induced apoptosis of cultured cardiac myocytes. J Pathol 193 (2001) 546-556
32. Lee P., Sata M., Lefer D.J., Factor S.M., Walsh K., and Kitsis R.N. Fas pathway is a critical mediator of cardiac myocyte death and MI during ischemia-reperfusion in vivo. Am J Physiol Heart Circ Physiol 284 (2003) H456-H463
33. Adamopoulos S., Parissis J.T., Georgiadis M., et al. Growth hormone administration reduces circulating proinflammatory cytokines and soluble Fas/soluble Fas ligand system in patients with chronic heart failure secondary to idiopathic dilated cardiomyopathy. Am Heart J 144 (2002) 359-364
34. Parissis J.T., Adamopoulos S., Karatzas D., Paraskevaidis J., Livanis E., and Kremastinos D. Growth hormone-induced reduction of soluble apoptosis mediators is associated with reverse cardiac remodelling and improvement of exercise capacity in patients with idiopathic dilated cardiomyopathy. Eur J Cardiovasc Prev Rehabil 12 2 (2005) 164-168
35. Villavicencio A., Iniguez G., Johnson M.C., Gabler F., Palomino A., and Vega M. Regulation of steroid synthesis and apoptosis by insulin-like growth factor 1 and insulin-like growth factor binding protein 3 in human corpus luteum during the midluteal phase. Reproduction 124 (2002) 501-508
36. Harrison M., Dunger A.M., Berg S., et al. Growth factor protection against cytokine-induced apoptosis in neonatal rat islets of Langerhans: role of Fas. FEBS Lett 435 (1998) 207-210
37. Kanoh M., Takemura G., Misao J., et al. Significance of myocytes with positive DNA in situ nick end-labeling (TUNEL) in hearts with dilated cardiomyopathy. Circulation 99 (1999) 2757-2764
38. Ohno M., Takemura G., and Ohno A. "Apoptotic" myocytes in infarct area in rabbit hearts may be oncotic myocytes with DNA fragmentation: analysis by immunogoldelectron microscopy combined with In situ nick end-labeling. Circulation 98 (1998) 1422-1430
39. Saraste A., and Pulkki K. Morphologic and biochemical hallmarks of apoptosis. Cardiovasc Res 45 (2000) 528-537
40. Pulkki A.S., and Voipio-Pulkki L.M. Significance of myocytes with positive DNA in situ nick end-labeling (TUNEL) in hearts with dilated cardiomyopathy. Circulation (2000) 101
41. Feuerstein G.Z., and Young P.R. Apoptosis in cardiac diseases: stress- and mitogen-activated signaling pathways. Cardiovasc Res 45 (2000) 560-569
42. Isgaard J., Carlsson L., Isaksson O.G.P., et al. Pulsatile intravenous growth hormone (GH) infusion to hypophysectomised rats increases insulin-like growth factor I messenger ribonucleic acid more effectively than continuous growth hormone infusion. Endocrinology 123 (1988) 2605-2610